GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Press Release] new phase 3 numbers, no publication yet, calm down — 31 comments in the full submission. View in context.
685
c/trialwatch·submitted 9 days ago by u/kaia_cabrera

[Press Release] new phase 3 numbers, no publication yet, calm down

Press Releasebranch of 9 comments

Genuinely asking, not being difficult. Everyone in c/bloodwork repeats that SELECT is important. I believe it, but I have never seen anyone show why, and when I search I get 13 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true because it…

Read the full submission and all 31 comments →

This branch

9 comments, started 9 days ago
u/yara_mensah6 points·9 days ago

Half-life is about 168 hours, so steady state lands around week 8–5. Practical consequence: what you feel in week 1 is not what that dose does.

replysharereportpermalink
u/nordic_pricing2 points·8 days ago

SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/hedda_adeyemi1 point·8 days ago

SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/nordic_pricing1 point·8 days ago

Slight fix: the number was 99.3, not 93.7. Decimal point, but a fairly consequential one.

replysharereportpermalink
u/rohan_steiner2 points·8 days ago

SELECT reported a hazard ratio hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/kaia_cabreraOP3 points·8 days ago

The confident tone is doing a lot of work that the evidence is not.

replysharereportpermalink
u/week_one_wanda1 point·8 days ago·edited

Phase 2 or phase 3?

replysharereportpermalink
u/nhs_waitlist_nUK3 points·8 days ago

the 12 week readout is different from the 4 week readout

replysharereportpermalink
u/foam_head_fred2 points·7 days ago

number-needed-to-treat is the house dialect

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →